Characteristics of r/r BCP-ALL patients prior to blinatumomab therapy
| Patient . | Age . | Sex . | Ph . | Interval ID - blinatumomab (mo) . | Prior therapies . | Cytoreductive therapy prior to blinatumomab . | Start of cytoreductive therapy prior to blinatumomab . | Prior allo-SCT . | Blast % (BM) prior to blinatumomab . | Days sampled under blinatumomab . |
|---|---|---|---|---|---|---|---|---|---|---|
| R1 | 37 | m | − | 21 | GMALL induction I, II and consolidation I conditioning therapy for allo-SCT: TBI (3 × 6 Gy), cyclophosphamide | Vin/Dex | day −12 | + | 54 | 48 |
| R2 | 35 | m | − | 9 | GMALL induction I, II; HAM, FLAG | Vin | day −17 | − | 30 (PB) | 14/21 |
| R3 | 51 | m | − | 32 | GMALL protocol (<55a, complete) | Cy | day −4 | − | 40 | 0/7/28 |
| R4 | 32 | m | − | 5 | GMALL induction I, II | − | − | − | 52 | 1/8/28 |
| R5 | 30 | f | − | 32 | GMALL protocol (<55a, complete); repeated GMALL induction I | − | − | − | 5 | 1/7/22 |
| R6 | 70 | f | + | 18 | EWALL elderly (complete, including dasatinib) | Cy/Dex | day −9 | − | 88 | −2/12/28 |
| R7 | 68 | f | − | 4 | GMALL elderly (induction I, II) | − | − | − | 24 | 0/7/42 |
| R8 | 32 | f | − | 11 | GMALL induction I, II and consolidation I conditioning therapy for allo-SCT: TBI (3 × 4 Gy), etoposide | − | − | + | 70 | 0/21 |
| R9 | 58 | m | − | 14 | GMALL protocol (<55a, until consolidation IV) | FLAG-Ida | day −10 | − | 60 | −1/7/44 |
| R10 | 34 | m | − | 22 | GMALL induction I, II and consolidation I conditioning therapy for allo-SCT: FLAMSA - TBI (2 × 4 Gy) | − | − | + | 8 | −1/7 |
| R11 | 22 | m | − | 7 | GMALL induction I, II and consolidation I FLAG-Ida | Cy/Dox/Vin | day −8 | − | 2 | 8/28/44 |
| R12 | 20 | m | − | 46 | CoALL protocol (complete); GMALL induction I, II and consolidation I, imatinib | − | − | − | 70 | 0/16/22 |
| R13 | 72 | m | − | 5 | GMALL elderly (induction I, II, and consolidation I, II) | Cy | day −4 | − | 39 | 0/8/15 |
| Patient . | Age . | Sex . | Ph . | Interval ID - blinatumomab (mo) . | Prior therapies . | Cytoreductive therapy prior to blinatumomab . | Start of cytoreductive therapy prior to blinatumomab . | Prior allo-SCT . | Blast % (BM) prior to blinatumomab . | Days sampled under blinatumomab . |
|---|---|---|---|---|---|---|---|---|---|---|
| R1 | 37 | m | − | 21 | GMALL induction I, II and consolidation I conditioning therapy for allo-SCT: TBI (3 × 6 Gy), cyclophosphamide | Vin/Dex | day −12 | + | 54 | 48 |
| R2 | 35 | m | − | 9 | GMALL induction I, II; HAM, FLAG | Vin | day −17 | − | 30 (PB) | 14/21 |
| R3 | 51 | m | − | 32 | GMALL protocol (<55a, complete) | Cy | day −4 | − | 40 | 0/7/28 |
| R4 | 32 | m | − | 5 | GMALL induction I, II | − | − | − | 52 | 1/8/28 |
| R5 | 30 | f | − | 32 | GMALL protocol (<55a, complete); repeated GMALL induction I | − | − | − | 5 | 1/7/22 |
| R6 | 70 | f | + | 18 | EWALL elderly (complete, including dasatinib) | Cy/Dex | day −9 | − | 88 | −2/12/28 |
| R7 | 68 | f | − | 4 | GMALL elderly (induction I, II) | − | − | − | 24 | 0/7/42 |
| R8 | 32 | f | − | 11 | GMALL induction I, II and consolidation I conditioning therapy for allo-SCT: TBI (3 × 4 Gy), etoposide | − | − | + | 70 | 0/21 |
| R9 | 58 | m | − | 14 | GMALL protocol (<55a, until consolidation IV) | FLAG-Ida | day −10 | − | 60 | −1/7/44 |
| R10 | 34 | m | − | 22 | GMALL induction I, II and consolidation I conditioning therapy for allo-SCT: FLAMSA - TBI (2 × 4 Gy) | − | − | + | 8 | −1/7 |
| R11 | 22 | m | − | 7 | GMALL induction I, II and consolidation I FLAG-Ida | Cy/Dox/Vin | day −8 | − | 2 | 8/28/44 |
| R12 | 20 | m | − | 46 | CoALL protocol (complete); GMALL induction I, II and consolidation I, imatinib | − | − | − | 70 | 0/16/22 |
| R13 | 72 | m | − | 5 | GMALL elderly (induction I, II, and consolidation I, II) | Cy | day −4 | − | 39 | 0/8/15 |
allo-SCT, allogeneic stem cell transplantation; BCP-ALL, B-cell precursor acute lymphoblastic leukemia; BM, bone marrow; Cy, cyclophosphamide; Dex, dexamethasone; Dox, doxorubicin; EWALL, European Working Group on Adult ALL; f, female; FLAG-Ida, fludarabine, Ara-C, G-CSF–idarubicin; FLAMSA, Fludarabin, Ara-C, Amsacrine; GMALL, German Multicenter Study Group For Adult ALL; ID, initial diagnosis; m, male; mo, month; PB, peripheral blood; Ph, Philadelphia chromosome; r/r, relapsed/refractory; TBI, total body irradiation; Vin, vincristine.